Xie J, et al. - Researchers sought to determine population-based estimates for prognosis among patients with liver metastases in newly diagnosed breast cancer querying the Surveillance, Epidemiology and End Results (SEER) database. From 2010 to 2014, 298,370 patients with breast cancer and 4,285 patients (1.4% of the entire cohort, 29.6% of the subset with metastatic disease) diagnosed with initial liver metastases were identified. Highest incidence proportions were evident among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (4.4% of entire cohort, 52.5% of patients with metastatic disease to any distant site) and HR-positive HER2-positive (2.8% of entire cohort, 40.4% of patients with metastatic disease to any distant site) subtypes. Patients with liver metastases in the entire cohort had a median survival of 15.0 months. The longest median survival (31.0 months) was observed for patients with HR-positive HER2-positive subtype showed; however, shortest median survival (8.0 months) was noted for patients with triple-negative subtype. Outcomes thus support the diagnosis of the liver in high-risk patients, including those with HER2-positive and other systemic metastases.